Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001182777 | SCV001348342 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-01-17 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with valine at codon 606 of the APC protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may create a splice donor site. However, this prediction has not been confirmed in published RNA studies. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV001182777 | SCV002711031 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-11-03 | criteria provided, single submitter | clinical testing | The p.I606V variant (also known as c.1816A>G), located in coding exon 14 of the APC gene, results from an A to G substitution at nucleotide position 1816. The isoleucine at codon 606 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, in silico predictors for this gene do not accurately predict pathogenicity. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV003469300 | SCV004199554 | uncertain significance | Familial adenomatous polyposis 1 | 2023-10-06 | criteria provided, single submitter | clinical testing |